News Medical18h
Scottish Medicines Consortium approves Libtayo as second-line treatment for advanced cervical cancer
Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...
The Lancet1d
Identifying key randomised clinical trials that could transform clinical care and public health
Clinical trials have been pivotal to the improvements in public health and clinical care, leading to many millions of ...
HUB1d
NIH funds research that leads directly to cancer treatments, clinical trials
Cancer researcher Karen Sfanos says she is 'terrified' of the impact of cuts to NIH funding that supports vital biomedical ...
Dual-target drug may lead to new treatment approach for breast cancer patients
Researchers, led by the University of Melbourne's Professor Laura Mackay, a Laboratory Head and Immunology Theme Leader at ...
Hosted on MSN2d
Rallybio doses first subject in Phase II trial of treatment for FNAIT in Europe
US-based biotechnology company Rallybio has dosed the first subject in a Phase II trial evaluating RLYB212 as a potential ...
Cure Today4d
THIO and Libtayo Extends OS in NSCLC Following Progression on SOC Therapy
THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who progressed on two or more ...
PharmiWeb4d
Libtayo® (cemiplimab) Now Available on the National Health Service in Scotland for Patients with Recurrent or Metastatic Cervical Cancer
Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...